Adverum Biotechnologies(US:ADVM) Globenewswire·2024-02-01 22:30Core Insights - Adverum Biotechnologies is set to present preliminary safety and efficacy data from its LUNA Phase 2 study of Ixo-vec for wet age-related macular degeneration (AMD) on February 8, 2024 [1][2] - The presentation will be made by Dr. Arshad M. Khanani at the 47th Annual Meeting of the Macula Society, highlighting results from both 2E11 and 6E10 dose levels [2] - The LUNA study was fully enrolled in August 2023, indicating significant progress in the clinical trial [1] Company Overview - Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company focused on establishing gene therapy as a new standard of care for prevalent ocular diseases [4] - The company aims to develop functional cures to restore vision and prevent blindness through its proprietary intravitreal (IVT) platform [4] - Ixo-vec is being evaluated as a one-time IVT injection for patients with neovascular or wet AMD, aiming to reduce the need for frequent ocular injections [4]